Compare · AXNX vs BDX
AXNX vs BDX
Side-by-side comparison of Axonex AI Group Limited (AXNX) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- AXNX operates in Consumer Discretionary, while BDX operates in Health Care - the two are in different parts of the market.
- BDX is the larger of the two at $58.96B, about 9369.0x AXNX ($6.3M).
- BDX has hit the wire 11 times in the past 4 weeks while AXNX has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 21 for AXNX).
- Company
- Axonex AI Group Limited
- Becton Dickinson and Company
- Price
- -
- -
- Market cap
- $6.3M
- $58.96B
- 1M return
- -
- +12.87%
- 1Y return
- -
- +44.14%
- Industry
- Business Services
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 0
- 11
- Recent ratings
- 21
- 25
Axonex AI Group Limited
Axonex AI Group Limited (formerly Mint Incorporation Limited) (NASDAQ: AXNX) is a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider. Through its subsidiary, Axonex AI Limited, and its majority owned subsidiary, Rice Robotics AGI Holding Limited, the Group delivers robot models and robotics solutions, including the FLOKI Minibot M1 and micro-insurance solutions purpose-built for commercial robots. The Group also maintains its established interior design and fit-out works business. Anchored by its ongoing transformation, Axonex AI is focused on AI and robotics as its main growth driving engine.
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest AXNX
- Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split
- Axonex AI Group Joins FLAIR’s Embodied AI International Applications Hub and Launches Education Humanoid TOMO
- Axonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused Company
- CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors
- RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
- SEC Form 15-12G filed by Axonics Inc.
- SEC Form EFFECT filed by Axonics Inc.
- SEC Form 25-NSE filed by Axonics Inc.
- Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)
Latest BDX
- Director Huffines Robert Luther was granted 158 units of Rights to Common Stock Under BD Deferred Compensation Plan (SEC Form 4)
- Director Byington Carrie L was granted 79 units of Rights to Common Stock Under 1996 Directors Deferral Plan (SEC Form 4)
- BD to Host Investor Day on December 10, 2026
- Chairman, CEO and President Polen Thomas E Jr exercised 20,239 shares at a strike of $178.94, returned $3,621,660 worth of shares to the company (17,246 units at $210.00) and sold $628,530 worth of shares (2,993 units at $210.00) as part of a pre-agreed trading plan (SEC Form 4)
- Becton Dickinson upgraded by Wells Fargo with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
- BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
- BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
- BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options